Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ranbaxy Runs Afoul Of FDA, Again

by Jean-François Tremblay
February 3, 2014 | A version of this story appeared in Volume 92, Issue 5

FDA has banned U.S. imports of active pharmaceutical ingredients from Ranbaxy Laboratories’ plant in Toansa, India. The agency found that Toansa plant operators retested failed batches of raw materials, intermediates, and finished ingredients in the hope of obtaining acceptable results. Since January 2012, Ranbaxy has been operating under the terms of a consent decree that required the company to pay a fine of $500 million and follow current Good Manufacturing Practices (cGMP) at facilities that were in violation in both Paonta Sahib and Dewas, India.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.